19.80
price up icon3.61%   0.69
after-market Handel nachbörslich: 19.53 -0.27 -1.36%
loading

Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten

pulisher
09:11 AM

Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting - The Manila Times

09:11 AM
pulisher
Nov 04, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $43.00 Consensus Price Target from Analysts - Defense World

Nov 04, 2024
pulisher
Nov 01, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 01, 2024
pulisher
Oct 26, 2024

Insiders of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) must be disappointed as stock fell 10% after recent purchases - Simply Wall St

Oct 26, 2024
pulisher
Oct 18, 2024

Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock - Yahoo Finance

Oct 18, 2024
pulisher
Oct 16, 2024

Multiple Myeloma Pipeline Insights and Analysis 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Cartesian Therapeutics, Rapa Therapeutics - Barchart

Oct 16, 2024
pulisher
Oct 16, 2024

Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 15, 2024
pulisher
Oct 15, 2024

Cartesian Therapeutics Announces Presentation of Results - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - StockTitan

Oct 15, 2024
pulisher
Oct 11, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Position Reduced by Renaissance Technologies LLC - MarketBeat

Oct 11, 2024
pulisher
Oct 09, 2024

30,038 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Purchased by Marshall Wace LLP - MarketBeat

Oct 09, 2024
pulisher
Oct 06, 2024

Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? - MSN

Oct 06, 2024
pulisher
Oct 05, 2024

Cartesian therapeutics director Timothy Springer buys $4.29m in stock By Investing.com - Investing.com South Africa

Oct 05, 2024
pulisher
Oct 04, 2024

Timothy A. Springer Acquires 80,301 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock - Defense World

Oct 04, 2024
pulisher
Oct 04, 2024

Insider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Acquires 5,514 Shares of Stock - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Cartesian therapeutics director Timothy Springer buys $4.29m in stock - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpHere's Why - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Cartesian Therapeutics Inc [NASDAQ: RNAC] Sees Increase in Stock Value - Knox Daily

Oct 04, 2024
pulisher
Oct 04, 2024

Cartesian Therapeutics Inc (RNAC) Stock: A Year of Highs and Lows - The InvestChronicle

Oct 04, 2024
pulisher
Oct 04, 2024

Emcore Corp. [EMKR] Records 50-Day SMA of $1.18 - Knox Daily

Oct 04, 2024
pulisher
Oct 04, 2024

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Oct 04, 2024
pulisher
Oct 03, 2024

Point72 DIFC Ltd Invests $47,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Oct 03, 2024
pulisher
Oct 01, 2024

Logos Global Management LP Takes Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Point72 Asia Singapore Pte. Ltd. Takes Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Logos Global Management LP Purchases Shares of 90,000 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat

Oct 01, 2024
pulisher
Sep 29, 2024

1,725 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Acquired by Point72 DIFC Ltd - Defense World

Sep 29, 2024
pulisher
Sep 29, 2024

Rhumbline Advisers Sells 121,396 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Sep 29, 2024
pulisher
Sep 29, 2024

Rhumbline Advisers Has $229,000 Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat

Sep 29, 2024
pulisher
Sep 25, 2024

Mizuho affirms Outperform on Cartesian Therapeutics stock, highlights Descartes-08’s competitive edge - Investing.com Canada

Sep 25, 2024
pulisher
Sep 24, 2024

Logos Global Management LP Invests $2.43 Million in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Cartesian Therapeutics gets shareholder nod for stock issuance By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 24, 2024

Logos Global Management LP Buys Shares of 90,000 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Bank of New York Mellon Corp Has $538,000 Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Cartesian Therapeutics gets shareholder nod for stock issuance - Investing.com

Sep 23, 2024
pulisher
Sep 18, 2024

Cartesian Therapeutics Puts Talent and Innovation at the Heart of the Organization - BioBuzz

Sep 18, 2024
pulisher
Sep 17, 2024

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results (NASDAQ:RNAC) - Seeking Alpha

Sep 17, 2024
pulisher
Sep 15, 2024

HC Wainwright Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World

Sep 15, 2024
pulisher
Sep 13, 2024

Cartesian Therapeutics' (RNAC) Buy Rating Reiterated at HC Wainwright - MarketBeat

Sep 13, 2024
pulisher
Sep 12, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Sep 12, 2024
pulisher
Sep 12, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Sep 12, 2024
pulisher
Sep 09, 2024

Cartesian Therapeutics Receives FDA Rare Pediatric Disease - GlobeNewswire

Sep 09, 2024
pulisher
Sep 09, 2024

FDA grants rare pediatric status for Cartesian’s Descartes-08 - The Pharma Letter

Sep 09, 2024
pulisher
Sep 09, 2024

Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment - MarketWatch

Sep 09, 2024
pulisher
Sep 09, 2024

Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis - Yahoo Finance

Sep 09, 2024
pulisher
Sep 06, 2024

Cartesian Therapeutics Doses First Patient With mRNA CAR-T Descartes-15 in Trial for R/R Multiple Myeloma - CGTLive™

Sep 06, 2024
pulisher
Sep 06, 2024

Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewswire

Sep 06, 2024
pulisher
Sep 05, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from HC Wainwright - Defense World

Sep 05, 2024
pulisher
Sep 04, 2024

HC Wainwright Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

Sep 04, 2024
pulisher
Sep 04, 2024

Cartesian Therapeutics shares maintain Buy rating as new trial kicks off - Investing.com Canada

Sep 04, 2024
pulisher
Sep 03, 2024

Cartesian advances new mRNA therapy into Phase 1 trial - Investing.com India

Sep 03, 2024
pulisher
Sep 03, 2024

Cartesian advances new mRNA therapy into Phase 1 trial By Investing.com - Investing.com Canada

Sep 03, 2024
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):